On this page
Cyclogyl
cyclopentolate hydrochloride · Solution/ Drops
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Cyclopentolate Hydrochloride | 10 mg/mL | 1298066 | — |
| Cyclopentolate Hydrochloride | 20 mg/mL | 1298066 | — |
| Cyclopentolate Hydrochloride | 5 mg/mL | 1298066 | — |
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 084110-001 | CYCLOGYL | SOLUTION/DROPS | CYCLOPENTOLATE HYDROCHLORIDE | Prescription | AT | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 36 | Labeling | Approved | October 31, 2003 | — |
| Supplement | 35 | Manufacturing (CMC) | Approved | December 23, 2002 | — |
| Supplement | 34 | Manufacturing (CMC) | Approved | October 11, 2002 | — |
| Supplement | 33 | Manufacturing (CMC) | Approved | November 20, 2001 | — |
| Supplement | 31 | Manufacturing (CMC) | Approved | April 28, 2000 | — |
| Supplement | 32 | Manufacturing (CMC) | Approved | April 7, 2000 | — |
| Supplement | 29 | Manufacturing (CMC) | Approved | May 7, 1999 | — |
| Supplement | 30 | Manufacturing (CMC) | Approved | March 23, 1999 | — |
| Supplement | 27 | Manufacturing (CMC) | Approved | March 4, 1999 | — |
| Supplement | 28 | Manufacturing (CMC) | Approved | December 9, 1998 | — |
| Supplement | 26 | Manufacturing (CMC) | Approved | February 17, 1998 | — |
| Supplement | 21 | Labeling | Approved | January 16, 1997 | — |
| Supplement | 25 | Manufacturing (CMC) | Approved | October 5, 1995 | — |
| Supplement | 24 | Manufacturing (CMC) | Approved | August 4, 1995 | — |
| Supplement | 23 | Manufacturing (CMC) | Approved | August 4, 1994 | — |
| Supplement | 22 | Labeling | Approved | August 3, 1994 | — |
| Supplement | 20 | Labeling | Approved | December 2, 1993 | — |
| Supplement | 17 | Manufacturing (CMC) | Approved | June 4, 1993 | — |
| Supplement | 16 | Manufacturing (CMC) | Approved | June 4, 1993 | — |
| Supplement | 19 | Manufacturing (CMC) | Approved | November 5, 1992 | — |
| Supplement | 18 | Labeling | Approved | July 29, 1992 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | February 20, 1991 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | February 20, 1991 | — |
| Supplement | 13 | Labeling | Approved | October 13, 1989 | — |
| Supplement | 12 | Labeling | Approved | August 28, 1989 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | March 9, 1989 | — |
| Supplement | 9 | Labeling | Approved | October 20, 1988 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | December 8, 1983 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | October 12, 1982 | — |
| Original application | 1 | Approved | July 31, 1974 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240625). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Cyclopentolate hydrochloride is used to produce mydriasis and cycloplegia.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: Adults: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 0.5%, 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary. Small Infants: A single instillation of one drop of 0.5% in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation. Individuals with heavily pigmented irides may require higher strengths.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Should not be used if the patient is hypersensitive to any component of this preparation.
Warnings
openFDA Drug LabelingWARNINGS: FOR TOPICAL OPHTHALMIC USE ONLY . NOT FOR INJECTION. This preparation may cause Central Nervous System (CNS) disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% CYCLOGYL solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation. Mydriatics may produce a transient elevation of intraocular pressure. Therefore, patients with untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure following administration.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported. Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.
Drug Interactions
openFDA Drug LabelingDrug Interactions: Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Description
openFDA Drug LabelingRx Only DESCRIPTION: CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. It is supplied in three strengths. The active ingredient is represented by the structural formula: Each mL of CYCLOGYL ® (cyclopentolate hydrochloride ophthalmic solution, USP) contains: Active: cyclopentolate hydrochloride 0.5%, 1% or 2%. Preservative: benzalkonium chloride 0.01%. Inactives: boric acid, edetate disodium, potassium chloride (except 2% strength), sodium carbonate and/or hydrochloric acid (to adjust pH), purified water. The pH range is between 3.0 and 5.5. chemical
Overdosage
openFDA Drug LabelingOVERDOSAGE: Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: In multiple-dose plastic DROP-TAINER® dispensers: 0.5% CYCLOGYL 1% CYCLOGYL 2% CYCLOGYL 15 mL NDC 0065-0395-15 2 mL NDC 0065-0396-02 2 mL NDC 0065-0397-02 5 mL NDC 0065-0396-05 5 mL NDC 0065-0397-05 15 mL NDC 0065-0396-15 15 mL NDC 0065-0397-15 Storage: Store at 8°C to 25°C (46°F to 77°F). After opening, Cyclogyl can be used until the expiration date on the bottle.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CYCLOPENTOLATE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0065-0395-15 | 0065-0395 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0395-15) / 15 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0396-02 | 0065-0396 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0396-02) / 2 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0396-05 | 0065-0396 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0396-05) / 5 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0397-02 | 0065-0397 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-02) / 2 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0397-05 | 0065-0397 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-05) / 5 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0397-15 | 0065-0397 | Alcon Laboratories, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (0065-0397-15) / 15 mL in 1 BOTTLE, PLASTIC | October 15, 1975 |
| 0065-0395 | 0065-0395 | Alcon Laboratories, Inc. | — | October 15, 1975 |
| 0065-0396 | 0065-0396 | Alcon Laboratories, Inc. | — | October 15, 1975 |
| 0065-0397 | 0065-0397 | Alcon Laboratories, Inc. | — | October 15, 1975 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.